zurück

Nivolumab (new indication: urothelial carcinoma, PD-L1-expression ≥ 1%, adjuvant therapy)


Subject:

  • Active Substance: Nivolumab
  • Name: Opdivo®
  • Therapeutic area: Urothelial carcinoma
  • Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA


Time table:

  • Start: 01.05.2022
  • Final decision by G-BA: 20.10.2022


Final decision:

  • Adult patients eligible for cisplatin-containing therapy for adjuvant treatment:
    No additional benefit proved
  • Adult patients not eligible for cisplatin-containing therapy for adjuvant treatment:
    No additional benefit proved